Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 537 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

First and Second-line Treatments in Metastatic Renal Cell Carcinoma.
Barragan-Carrillo R, Saad E, Saliby RM, Sun M, Albiges L, Bex A, Heng D, Mejean A, Motzer RJ, Plimack ER, Powles T, Rini BI, Zhang T, Choueiri TK
Eur Urol, S0302-2838(24)02681-2, 05 Nov 2024
Cited by: 0 articles | PMID: 39505582
Add to export list Review
Refining the Tissue Source for Biomarker-based Approaches in Renal Cell Carcinoma.
Haake SM, Rini BI
Eur Urol, S0302-2838(24)02624-1, 26 Sep 2024
Cited by: 0 articles | PMID: 39332931
Add to export list
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
Ornstein MC, George L, Wei W, Diaz-Montero CM, Rayman P, Martin A, Basu A, Beckermann KE, Nizam A, Wee CE, Gilligan TD, Gupta S, Rini BI
Clin Genitourin Cancer, 22(6):102181, 31 Jul 2024
Cited by: 0 articles | PMID: 39208489
Add to export list
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, [...] LITESPARK-005 Investigators
N Engl J Med, 391(8):710-721, 01 Aug 2024
Cited by: 1 article | PMID: 39167807
Add to export list
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.
Chang E, Zhou J, Song C, Gittleman H, Fernandes L, Weinstock C, Atkins MB, Agrawal S, Sridhara R, Gormley N, Tang S, Suzman DL, Amiri-Kordestani L, Kluetz PG, Pazdur R, Rini BI, McDermott DF, Regan MM
Clin Cancer Res, 30(15):3282-3286, 01 Aug 2024
Cited by: 0 articles | PMID: 38416426
Add to export list
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.
Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, [...] Motzer RJ
Ann Oncol, 35(11):1026-1038, 02 Aug 2024
Cited by: 1 article | PMID: 39098455
Add to export list
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
Mantia CM, Jegede OA, Plimack ER, Powles T, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albigès L, Rosenblatt L, Atkins MB, Regan MM, McDermott DF
J Immunother Cancer, 12(7):e009495, 25 Jul 2024
Cited by: 0 articles | PMID: 39060019 | PMCID: PMC11284827
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Impact of Targeted Systemic Therapy and Radiotherapy on Patients Undergoing Spine Surgery for Metastatic Renal Cell Carcinoma.
Chanbour H, Chen JW, Bendfeldt GA, Suryateja Gangavarapu L, LaBarge ME, Ahmed M, Younus I, Jonzzon S, Roth SG, Chotai S, Rini BI, Luo LY, Abtahi AM, Stephens BF, Zuckerman SL
Int J Spine Surg, 18(3):343-352, 04 Jul 2024
Cited by: 0 articles | PMID: 38964886 | PMCID: PMC11535771
Add to export list Free full text in Europe PMC
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma.
Brugarolas J, Obara G, Beckermann KE, Rini B, Lam ET, Hamilton J, Schluep T, Yi M, Wong S, Mao ZL, Gamelin E, Tannir NM
Clin Cancer Res, 30(11):2402-2411, 01 Jun 2024
Cited by: 0 articles | PMID: 38652038 | PMCID: PMC11145158
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, Saad E, Kane MH, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer RJ, Powles T, Rini BI, Albiges L, Pal SK, McGregor BA, McKay RR, [...] Braun DA
Cancer Cell, 42(5):732-735, 04 Apr 2024
Cited by: 1 article | PMID: 38579722
Add to export list
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, Chevreau C, Tannir NM, Oudard S, McDermott DF, Laguerre B, Hammers HJ, Barthelemy P, Plimack ER, Borchiellini D, Gross-Goupil M, Jiang R, Lee CW, de Silva H, [...] Albigès L
Eur J Cancer, 204:114048, 08 Apr 2024
Cited by: 2 articles | PMID: 38653033
Add to export list
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E
Oncologist, 29(3):254-262, 01 Mar 2024
Cited by: 1 article | PMID: 38262444 | PMCID: PMC10911910
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
Choueiri TK, Donahue AC, Braun DA, Rini BI, Powles T, Haanen JBAG, Larkin J, Mu XJ, Pu J, Teresi RE, di Pietro A, Robbins PB, Motzer RJ
Cancer Discov, 14(3):406-423, 01 Mar 2024
Cited by: 0 articles | PMID: 38385846 | PMCID: PMC10905671
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Beckermann KE, Patnaik A, Winer I, Tan W, Bashir B, Kyriakopoulos CE, Sweis RF, Chamberlain M, Rini BI
Invest New Drugs, 42(2):179-184, 19 Feb 2024
Cited by: 2 articles | PMID: 38372949
Add to export list
PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy.
Hakimi K, Campbell SC, Nguyen MV, Rathi N, Wang L, Meagher MF, Rini BI, Ornstein M, McKay RR, Derweesh IH
BJU Int, 133(4):425-431, 11 Jan 2024
Cited by: 0 articles | PMID: 37916303
Add to export list
Microbiome subsets determine tumor prognosis and molecular characteristics of clear-cell renal cell carcinoma: a multi-center integrated analysis of microbiome, metabolome, and transcriptome data.
Chen W, Pan X, Zhou W, Xu D, Chen J, Dong K, Chen W, Rini B, Cui X
Front Med, 18(2):399-402, 15 Dec 2023
Cited by: 0 articles | PMID: 38097819
Add to export list
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, [...] Rini BI
Eur Urol, 85(2):e58-e59, 08 Dec 2023
Cited by: 1 article | PMID: 38071169
Add to export list
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Choueiri TK, Powles T, Voss MH, Plimack ER, Gurney H, Song Y, Perini RF, Rodriguez-Lopez K, Rini BI
Future Oncol, 19(40):2631-2640, 26 Oct 2023
Cited by: 3 articles | PMID: 37882432
Add to export list Review
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Oya M, Albiges L, Aizawa M, Umeyama Y, Wang J, di Pietro A, Schmidinger M
ESMO Open, 8(6):102034, 20 Oct 2023
Cited by: 2 articles | PMID: 37866029 | PMCID: PMC10774904
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Rhoda Molife L, [...] Rini BI
Eur Urol, 84(5):e123-e124, 02 Sep 2023
Cited by: 0 articles | PMID: 37666734
Add to export list
A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma.
Beckermann KE, Rini BI
Nat Rev Clin Oncol, 20(9):581-582, 01 Sep 2023
Cited by: 0 articles | PMID: 37353556
Add to export list
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, [...] Rini BI
Eur Urol, 84(5):449-454, 25 Jul 2023
Cited by: 14 articles | PMID: 37500340
Add to export list
Sequencing checkpoint inhibitor therapy in renal cell carcinoma.
Beckermann KE, Rini BI
Lancet, 402(10397):160-161, 05 Jun 2023
Cited by: 1 article | PMID: 37290460
Add to export list
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
Bergerot CD, Malhotra J, Bergerot P, Philip EJ, Castro DV, Hsu J, Mota ACA, Cardoso de Azeredo A, Neto JNM, Hutson T, Grünwald V, Bex A, Psutka SP, Rini B, Plimack ER, Master V, Albiges L, Choueiri TK, Pal S, Powles T
Oncologist, 28(6):494-500, 01 Jun 2023
Cited by: 1 article | PMID: 36917626 | PMCID: PMC10243758
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB, Schmidinger M, Penkov K, Michelon E, Wang J, Mariani M, di Pietro A, Motzer RJ
ESMO Open, 8(3):101210, 25 Apr 2023
Cited by: 12 articles | PMID: 37104931 | PMCID: PMC10265611
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 537 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Partnerships & funding